MktsMarkets

Xilio Therapeutics, Inc.
NASDAQ: XLOKey statistics
XLO News
Stories mentioning XLO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 12,648 | 13,686 | 19,066 | 8,084 | 2,930 | 2,263 | 2,357 | |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 19,832 | 18,122 | 14,321 | 15,330 | 8,266 | 8,836 | 10,759 | 11,216 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 26,760 | 25,522 | 20,995 | 22,450 | 16,781 | 15,353 | 17,025 | 17,061 |
| Operating Income (Loss) | (14,112) | (11,836) | (1,929) | (14,366) | (13,851) | (13,629) | (14,762) | (14,704) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 1,283 | 921.00 | 1,022 | (1,428) | 586.00 | 536.00 | 742.00 | 779.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (9,529) | 10,360 | (16,287) | (15,844) | (13,265) | (13,093) | (14,020) | (13,925) |
| Earnings Per Share (Basic) | (0.58) | 1.24 | (0.11) | (0.16) | (2.49) | (3.43) | (0.22) | (0.24) |
| Earnings Per Share (Diluted) | (0.58) | (1.43) | (0.11) | (0.16) | (2.49) | (14.16) | (0.22) | (0.24) |
| Weighted Average Shares Outstanding (Basic) | 16,348 | 8,359 | 144,107 | 96,448 | 5,336 | 3,822 | 63,465 | 57,760 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About XLO
Xilio Therapeutics, Inc. (NASDAQ: XLO) is a stock listed on the Nasdaq Stock Market under the ticker symbol XLO. It last traded at $7.56 (Nov 20, 2026, 4:00 PM ET), up 0.7% on the day. That gives Xilio Therapeutics a market capitalisation of $52.7M.
Over the past 52 weeks XLO has traded between $6.47 and $11.30.
Revenue for the quarter ended Mar 31, 2026 was $12.6M; a net loss of $9.5M. Revenue was up 332% from $2.9M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $12.6M | -$9.5M | -75.3% |
| Dec 31, 2025 | $13.7M | $10.4M | 75.7% |
| Sep 30, 2025 | $19.1M | -$16.3M | -85.4% |
| Jun 30, 2025 | $8.1M | -$15.8M | -196.0% |
From Xilio Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…